NASDAQ$RNA

Atrium Therapeutics Inc · Q2 2021 earnings

Q2 2021 earnings ·

Headline financials

Total Revenue

$2.61M

Previous: $1.54M+69.2%
Capital Expenditures

-$1.23M

Previous: -$10K-12230.0%
Free Cash Flow

-$27.6M

Previous: -$10.6M-161.1%
Net Income

-$26.4M

Previous: -$10.6M-149.6%
Operating Income

-$26.4M

Previous: -$10.4M-154.3%
Gross Profit

$0.00

No prior period

Revenue & EPS history

Atrium Therapeutics Inc · Revenue · Quarterly

$2.61M

Q2 2021+69.2%vs Q2 2020
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Revenue by segment

Atrium Therapeutics Inc · $19.6M total across 1 segment · Q1 2026

  • Reportable Segment
    $19.6M—

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro